Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | NX-2127 |
Synonyms | |
Therapy Description |
NX-2127 is a small molecule that induces degradation of BTK, which may lead to inhibition of the growth of malignant B-cells (62nd ASH Annual Meeting and Exposition, Dec 2020, Abstract 2788). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NX-2127 | NX 2127|NX2127 | BTK inhibitor 35 | NX-2127 is a small molecule that induces degradation of BTK, which may lead to inhibition of the growth of malignant B-cells (62nd ASH Annual Meeting and Exposition, Dec 2020, Abstract 2788). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BTK C481S | diffuse large B-cell lymphoma | sensitive | NX-2127 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, NX-2127 inhibited proliferation of a diffuse large B-cell lymphoma cell line expressing BTK C481S in culture, and resulted in tumor growth inhibition in a cell line xenograft model (62nd ASH Annual Meeting and Exposition, Dec 2020, Abstract 2788). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04830137 | Phase I | NX-2127 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | 0 |